{"nctId":"NCT00098059","briefTitle":"Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection","startDateStruct":{"date":"2005-02"},"conditions":["Herpes Simplex"],"count":74,"armGroups":[{"label":"Famciclovir, pediatric oral formulation","type":"EXPERIMENTAL","interventionNames":["Drug: Famciclovir"]}],"interventions":[{"name":"Famciclovir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History or laboratory evidence of herpes simplex infection\n* Clinical evidence or suspicion of herpes simplex infection\n\nExclusion Criteria:\n\n* Patients unable to swallow\n* Concomitant use of probenecid\n* Positive pregnancy test\n\nAdditional protocol-defined inclusion/exclusion criteria may apply. For detailed information on eligibility, please contact the study center nearest to you or call the following numbers: 1-862-778-3544 or 1-434-951-3228","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"12 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Overall Acceptability of Pediatric Oral Formulation by Patients in Part A of the Study.","description":"Overall acceptability of the study medication was determined by caretaker response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study.","description":"Overall acceptability of the study medication was determined by caretaker response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study","description":"Overall acceptability of study medication was determined by caretaker response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety and Tolerability of a Single-dose of Famciclovir in Part A of the Study.","description":"A patient with multiple adverse events (AEs) within the primary system organ class is counted only once in total row.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Maximum Observed Plasma Concentration of Penciclovir (Cmax)","description":"PK parameter; penciclovir is the active metabolite of famciclovir.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":"1.25"},{"groupId":"OG001","value":"2.44","spread":"0.94"},{"groupId":"OG002","value":"2.82","spread":"0.65"},{"groupId":"OG003","value":"1.89","spread":null}]}]}]},{"type":"PRIMARY","title":"Time of Maximum Observed Plasma Concentration of Penciclovir (Tmax)","description":"PK parameter; penciclovir is the active metabolite of famciclovir.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null},{"groupId":"OG001","value":"1.07","spread":null},{"groupId":"OG002","value":"1.00","spread":null},{"groupId":"OG003","value":"1.47","spread":null}]}]}]},{"type":"PRIMARY","title":"Area Under the Penciclovir Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-âˆž)","description":"PK parameter; penciclovir is the active metabolite of famciclovir.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.17","spread":"2.42"},{"groupId":"OG001","value":"6.85","spread":"1.55"},{"groupId":"OG002","value":"8.15","spread":"1.01"},{"groupId":"OG003","value":"5.93","spread":"0"}]}]}]},{"type":"PRIMARY","title":"Apparent Oral Clearance of Penciclovir (CL/F)","description":"PK parameter; penciclovir is the active metabolite of famciclovir.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":"8.5"},{"groupId":"OG001","value":"25.1","spread":"4.3"},{"groupId":"OG002","value":"43.7","spread":"9.6"},{"groupId":"OG003","value":"68.8","spread":"0"}]}]}]},{"type":"PRIMARY","title":"Apparent Terminal Elimination Half-life of Penciclovir (T1/2)","description":"PK parameter; penciclovir is the active metabolite of famciclovir","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"0.08"},{"groupId":"OG001","value":"1.36","spread":"0.20"},{"groupId":"OG002","value":"1.60","spread":"0.25"},{"groupId":"OG003","value":"1.86","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety and Tolerability of Famciclovir Pediatric Oral Formulation in Part B of the Study.","description":"A patient with multiple AEs within the primary system organ class is counted only once in total row.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Headache","Vomiting","Abdominal pain upper","Diarrhea","Pyrexia"]}}}